瑞達期貨(002961.SZ):董事會批准申請開展股票期權做市業務
格隆匯2月20日丨瑞達期貨(002961.SZ)公佈,公司第四屆董事會第十二次會議決議,審議通過《關於申請開展股票期權做市業務的議案》,為發揮公司全資子公司瑞達新控資本管理有限公司(“瑞達新控”)期權做市優勢,拓展業務服務的廣度,增強風險管理業務的活性,董事會同意公司依據相關法律法規的要求向監管機構申請開展股票期權做市業務,如獲核准,將由瑞達新控依據相關法律法規及業務規則的規定合規開展股票期權做市交易業務,並根據業務發展需要、風險承受能力、市場情況等相關因素,審慎決定具體業務所投入的資金額度及規模。
董事會授權公司經營管理層或其指定的有關人員具體辦理提交業務資格申請的相關手續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.